Procarbazine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100760

CAS#: 366-70-1 (HCl)

Description: Procarbazine is an antineoplastic chemotherapy drug for the treatment of Hodgkin's lymphoma and certain brain cancers (such as glioblastoma multiforme). It is a member of a group of medicines called alkylating agents. The drug is metabolized and activated in the liver. It also inhibits MAO thus increasing the effects of sympathomimetics, TCAs, and tyramine. It gained FDA Approved in July 1969. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.

Chemical Structure

Procarbazine HCl
CAS# 366-70-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 100760
Name: Procarbazine HCl
CAS#: 366-70-1 (HCl)
Chemical Formula: C12H20ClN3O
Exact Mass: 221.15281
Molecular Weight: 257.76
Elemental Analysis: C, 55.92; H, 7.82; Cl, 13.75; N, 16.30; O, 6.21

Price and Availability

Size Price Availability Quantity
50.0mg USD 150.0 Ready to ship
1.0g USD 250.0 Ready to ship
2.0g USD 350.0 Ready to ship
5.0g USD 550.0 Ready to ship
10.0g USD 950.0 Ready to ship
20.0g USD 1650.0 Ready to ship
100.0g USD 3650.0 Ready to ship
500.0g USD 8950.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 671-16-9 (free base)   366-70-1 (HCl)   18969-59-0 (HBr)    

Synonym: CB 400-497; NSC-77213; Ro 4-6467; Ro 4-6467/1; Procarbazine Hydrochloride; PCB Hydrochloride; PCZ; Procarbazin. Matulane. Natulan; Natulanar; Natunalar.

IUPAC/Chemical Name: N-isopropyl-4-((2-methylhydrazinyl)methyl)benzamide hydrochloride


InChi Code: InChI=1S/C12H19N3O.ClH/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3;/h4-7,9,13-14H,8H2,1-3H3,(H,15,16);1H


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Biological target: Procarbazine Hydrochloride is an alkylating agent, with anticancer activity.
In vitro activity: Electron spin resonance (ESR) analysis combined with the use of 4-pyridyl-1-oxide-t-butyl nitrone (4-POBN) and dibromonitroso benzenesulfonic acid (DBNBS) as spin-trapping agents was used to characterize free radical generation during the metabolism of the anticancer agent procarbazine [N-isopropyl-a-(2-methylhydrazino)-p-toluamide hydrochloride]. The formation of free radical species, identified as methyl radicals, was observed during oxidation of procarbazine in rat liver microsomes and isolated hepatocytes in vitro. The metabolic pathway leading to free radical formation was characterized using various procarbazine metabolites and revealed strict analogies with previously published data on methane production from procarbazine. These results supported the identification of the trapped species as methyl free radical and suggested that C-oxidation of azoprocarbazine is the main source of radical intermediates derived from this anticancer drug. Reference: Carcinogenesis. 1992 May;13(5):799-805.
In vivo activity: Flow cytometry-based erythrocyte and T lymphocyte assays were employed in order to quantify the frequencies of cells deficient in glycosylphosphatidyl inositol-anchored surface markers CD59 and CD48 (presumed mutants in the endogenous X-linked Pig-a gene) in rats. The rats were treated once daily with 100 mg/kg procarbazine HCl for 3 days. In addition, we sorted mutant-phenotype spleen T cells and immediately analysed their Pig-a gene using next generation sequencing of dual-indexed multiplex libraries and error-correcting data filtering. More than 100-fold increase in the frequencies of CD59-deficient RBCs was observed at Day 29 after the last administration, and a 10-fold increase in the frequency of CD48-deficient T cells was observed at Days 45 to 50. Sequencing revealed that, in T cells from procarbazine-treated rats, mutations in the Pig-a gene occurred predominantly at A:T basepairs when A was located on the non-transcribed DNA strand. A→T transversion was the most common mutation. The results suggest that, at least for the transcribed X-linked Pig-a gene, in vivo methyl guanine adducts are not the major contributors to mutations induced by procarbazine. Reference: Mutagenesis. 2017 Dec 31;32(6):571-579.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 25.0 97.0
Ethanol 2.0 7.8

Preparing Stock Solutions

The following data is based on the product molecular weight 257.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
In vitro protocol: 1. Goria-Gatti L, Iannone A, Tomasi A, Poli G, Albano E. In vitro and in vivo evidence for the formation of methyl radical from procarbazine: a spin-trapping study. Carcinogenesis. 1992 May;13(5):799-805. doi: 10.1093/carcin/13.5.799. PMID: 1316811.
In vivo protocol: 1. Revollo J, Bhalli JA, Tebbe C, Noteboom J, Thomas D, McKinzie P, Felton N, Pearce MG, Dobrovolsky VN. Spectrum of Pig-a mutations in T lymphocytes of rats treated with procarbazine. Mutagenesis. 2017 Dec 31;32(6):571-579. doi: 10.1093/mutage/gex032. PMID: 29237063. 2. Maurice C, Dertinger SD, Yauk CL, Marchetti F. Integrated In Vivo Genotoxicity Assessment of Procarbazine Hydrochloride Demonstrates Induction of Pig-a and LacZ Mutations, and Micronuclei, in MutaMouse Hematopoietic Cells. Environ Mol Mutagen. 2019 Jul;60(6):505-512. doi: 10.1002/em.22271. Epub 2019 Jan 18. PMID: 30592561; PMCID: PMC6618172.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

  1: Yap KY, Tay WL, Chui WK, Chan A. Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur J Cancer Care (Engl). 2009 Dec 17. [Epub ahead of print] PubMed PMID: 20030690.

2: Roos WP, Nikolova T, Quiros S, Naumann SC, Kiedron O, Zdzienicka MZ, Kaina B. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst). 2009 Jan 1;8(1):72-86. Epub 2008 Oct 21. PubMed PMID: 18840549.

3: Ribrag V, Koscielny S, Casasnovas O, Cazeneuve C, Brice P, Morschhauser F, Gabarre J, Stamatoullas A, Lenoir G, Salles G; Groupe d'Etude des Lymphomes agressifs group, Laboratoire de Génétique et de recherche translationnelle, and Institut Gustave Roussy. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. Blood. 2009 Apr 2;113(14):3307-13. Epub 2008 Sep 3. PubMed PMID: 18768784.

4: Krawczuk-Rybak M, Leszczyńska E, Wysocka J, Zelazowska-Rutkowska B. [Anti-mullerian hormone in young women after chemotherapy and infradiaphragmatic radiotherapy for childhood cancer]. Pediatr Endocrinol Diabetes Metab. 2008;14(2):99-103. Polish. PubMed PMID: 18721496.

5: Glen CD, Smith AG, Dubrova YE. Single-molecule PCR analysis of germ line mutation induction by anticancer drugs in mice. Cancer Res. 2008 May 15;68(10):3630-6. PubMed PMID: 18483245.

6: Gasowska-Bajger B, Wojtasek H. Indirect oxidation of the antitumor agent procarbazine by tyrosinase--possible application in designing anti-melanoma prodrugs. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3296-300. Epub 2008 Apr 22. PubMed PMID: 18457951.

7: Armand JP, Ribrag V, Harrousseau JL, Abrey L. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag. 2007 Jun;3(2):213-24. PubMed PMID: 18360630; PubMed Central PMCID: PMC1936303.

8: Grossman SA, Carson KA, Batchelor TT, Lesser G, Mikkelsen T, Alavi JB, Phuphanich S, Hammour T, Fisher JD, Supko JG. The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride. Clin Cancer Res. 2006 Sep 1;12(17):5174-81. PubMed PMID: 16951236.

9: Giordana MT, Ghimenti C, Leonardo E, Balteri I, Iudicello M, Duò D. Molecular genetic study of a metastatic oligodendroglioma. J Neurooncol. 2004 Feb;66(3):265-71. PubMed PMID: 15015656.

10: Ewesuedo RB, Dolan ME. Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat. Cancer Chemother Pharmacol. 2000;46(2):150-5. PubMed PMID: 10972485.